<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522807</url>
  </required_header>
  <id_info>
    <org_study_id>B3301007</org_study_id>
    <nct_id>NCT01522807</nct_id>
  </id_info>
  <brief_title>A Study Of Three PF-05190457 Formulations In Healthy Volunteers</brief_title>
  <official_title>A Phase I, Cross-Over, Single Dose, Double-Blind Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-05190457 In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the plasma drug concentrations of three formulations
      of PF-05190457 after administration of single doses to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameters of Area Under the Curve (AUC) and its ratio between formulations as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameters of Maximum Concentration (Cmax) and its ratio between formulations as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Time of Maximum concentration (Tmax) as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The single dose pharmacokinetics of PF-05190457 in three formulations will be described by estimating parameter of Elimination of half-life (t Â½ ) as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ratio of fasted to fed single dose pharmacokinetics of PF-05190457 in two test formulations will be described by estimating parameters of Area Under the Curve (AUC) and its ratio between fed states as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of fasted to fed single dose pharmacokinetics of PF-05190457 in two test formulations will be described by estimating parameters of Maximum Concentration (Cmax) and its ratio between fed states as data permit.</measure>
    <time_frame>0 - 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma glucose and insulin due to single doses of three formulations of PF-05190457 will be estimated.</measure>
    <time_frame>0 - 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>100 mg PF-05190457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three fasted treatments and fed with the short-duration osmotic capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PF - 05190457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three fasted treatments and fed with the long-duration osmotic capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state</description>
    <arm_group_label>100 mg PF-05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state</description>
    <arm_group_label>100 mg PF-05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state</description>
    <arm_group_label>100 mg PF-05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state</description>
    <arm_group_label>100 mg PF-05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state</description>
    <arm_group_label>100 mg PF - 05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state</description>
    <arm_group_label>100 mg PF - 05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state</description>
    <arm_group_label>100 mg PF - 05190457</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05190457</intervention_name>
    <description>100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state</description>
    <arm_group_label>100 mg PF - 05190457</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females of non-childbearing potential between ages of 21 and 55
             years, BMI of 17.5 to 30.5 kg/m^2, and weight above 50 kg.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3301007&amp;StudyName=A%20Study%20Of%20Three%20PF-05190457%20Formulations%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 27, 2012</last_update_submitted>
  <last_update_submitted_qc>January 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Single Doses</keyword>
  <keyword>Biocomparison</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

